Connection
Robert Jotte to Tumor Microenvironment
This is a "connection" page, showing publications Robert Jotte has written about Tumor Microenvironment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.035 |
|
|
|
-
He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023 07; 18(7):907-921.
Score: 0.035